Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM6A | O15550 | 1/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.44 |
| ▸ | KDM4B | O94953 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17084052 | 0.84 | RPS6KB1 (0.56) | RPS6KB1AURKAAURKB | |
| SCHEMBL8511274 | 0.81 | SMN1; SMN2 (0.49) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL1460979 | 0.81 | NAPRT (0.49) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL12076025 | 0.81 | ALDH1A1 (0.46) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL667108 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1RPS6KB1AURKAPSMD14 | |
| SCHEMBL3642591 | 0.77 | MAPT (0.43) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL14575046 | 0.77 | RPS6KB1 (0.52) | RPS6KB1AURKAAURKB | |
| SCHEMBL1462136 | 0.77 | TSHR (0.51) | KDM4ERAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL23497087 | 0.76 | RPS6KB1 (0.40) | RPS6KB1AURKAAURKB | |
| SCHEMBL30011123 | 0.76 | RPS6KB1 (0.40) | RPS6KB1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-4072670-B1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-22 | — | — | EP | disclosed |
| EP-4072670-B1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-22 | — | — | EP | disclosed |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-02 | — | — | US | disclosed |
| EP-4072670-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-10-19 | — | — | EP | disclosed |
| CN-114786771-A | Quinazoline derivatives as inhibitors of LPA receptor 2 | 奇斯药制品公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021116260-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116260-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-06-17 | — | — | WO | disclosed |
| CN-102317269-B | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2015-06-17 | — | — | CN | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2011-03-03 | — | — | US | disclosed |
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2011-03-03 | — | — | US | disclosed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
| EP-2170842-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM, LLC (BM) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687821-A | Protein kinase inhibitors and methods of use thereof | IRM LLC | 2010-03-31 | — | — | CN | disclosed |
| WO-2008157575-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157575-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | LPAR2, LPAR1, LPAR5 | KDM4E 3035/4885KDM4A 3049/4885EGLN1 3363/4885 |
| US-20110053932-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | BMX, FRK, FYN | KDM4E 1346/4885KDM4A 961/4885EGLN1 3350/4885 |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR1, LPAR5 | KDM4E 3035/4885KDM4A 3049/4885EGLN1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.